Markéta Škereňová1,2, Veronika Mikulová3, Otakar Čapoun4, David Švec5, Katarína Kološtová6, Viktor Soukup4, Hana Honová7, Tomáš Hanuš4, Tomáš Zima3. 1. Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, U Nemocnice 2, 12808, Prague, Czech Republic. jancikova.market@gmail.com. 2. Laboratory of Immunology and Allergology, Karlovo náměstí 32, 128 00, Prague, Czech Republic. jancikova.market@gmail.com. 3. Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, U Nemocnice 2, 12808, Prague, Czech Republic. 4. Department of Urology, General University Hospital and First Faculty of Medicine, Charles University in Prague, Ke Karlovu 6, 12808, Prague, Czech Republic. 5. Laboratory of Gene Expression, Institute of Biotechnology CAS, Průmyslová 595, 252 50, Vestec, Czech Republic. 6. Institute of Laboratory Diagnostics, Third Faculty of Medicine, Charles University in Prague, Šrobárova 1150/50, 100 34, Prague, Czech Republic. 7. Department of Oncology, General University Hospital in Prague and First Faculty of Medicine, Charles University in Prague, U Nemocnice 2, 12808, Prague, Czech Republic.
Abstract
BACKGROUND: Molecular characterization of tumors could be a key to therapeutic decision-making with regards to targeted therapies in castration-resistant prostate cancer (CRPC). A convenient solution may be non-invasive liquid biopsy testing of circulating tumor cells (CTCs). For this reason, CTC-enriched samples obtained by immunomagnetic separation (AdnaTest®) were studied as a source material for high-throughput gene expression analysis using BioMark™. PATIENTS AND METHODS: CTC-enriched samples from 41 CRPC patients previously determined to be CTC positive using the AdnaTest® were retrospectively re-analysed for androgen receptor (AR) messenger RNA (mRNA), using the updated AdnaTest®. Blood samples were drawn two times from each patient: at the time of CRPC diagnosis and after the third docetaxel cycle. A gene expression panel of 27 genes related to CRPC therapeutic decision-making, including AR full length (ARFL) and splice variant 7 (ARV7), was retrospectively analyzed on a BioMark™ platform in 29 of 41 patients. RESULTS: The AdnaTest® detected AR mRNA in three-quarters of CTC-positive samples taken at the time of CRPC diagnosis and after the third docetaxel cycle. AR detection was associated with a shorter disease-specific survival (45.0 vs. 20.4 months) at the time of CRPC diagnosis. ARFL expression at the time of CRPC diagnosis, measured on the BioMark™ platform, was associated with a lower decrease of serum level of prostate-specific antigen (sPSA) (p = 0.029), i.e., worse therapy response. ARV7 was found in 38% of the ARFL--positive samples at both analyzed timepoints. CONCLUSION: Detection of AR expression by AdnaTest® in CTC-enriched samples may help predict patients' survival. These AdnaTest® CTC-enriched samples can be used in a high-throughput quantitative polymerase chain reaction (qPCR) analysis of gene expression, provided that the specificity of the assay for each individual gene is properly validated. The BioMark™ platform can be used for the simultaneous detection of ARFL and ARV7 and other genes in CTC-enriched samples from CRPC patients.
BACKGROUND: Molecular characterization of tumors could be a key to therapeutic decision-making with regards to targeted therapies in castration-resistant prostate cancer (CRPC). A convenient solution may be non-invasive liquid biopsy testing of circulating tumor cells (CTCs). For this reason, CTC-enriched samples obtained by immunomagnetic separation (AdnaTest®) were studied as a source material for high-throughput gene expression analysis using BioMark™. PATIENTS AND METHODS: CTC-enriched samples from 41 CRPC patients previously determined to be CTC positive using the AdnaTest® were retrospectively re-analysed for androgen receptor (AR) messenger RNA (mRNA), using the updated AdnaTest®. Blood samples were drawn two times from each patient: at the time of CRPC diagnosis and after the third docetaxel cycle. A gene expression panel of 27 genes related to CRPC therapeutic decision-making, including AR full length (ARFL) and splice variant 7 (ARV7), was retrospectively analyzed on a BioMark™ platform in 29 of 41 patients. RESULTS: The AdnaTest® detected AR mRNA in three-quarters of CTC-positive samples taken at the time of CRPC diagnosis and after the third docetaxel cycle. AR detection was associated with a shorter disease-specific survival (45.0 vs. 20.4 months) at the time of CRPC diagnosis. ARFL expression at the time of CRPC diagnosis, measured on the BioMark™ platform, was associated with a lower decrease of serum level of prostate-specific antigen (sPSA) (p = 0.029), i.e., worse therapy response. ARV7 was found in 38% of the ARFL--positive samples at both analyzed timepoints. CONCLUSION: Detection of AR expression by AdnaTest® in CTC-enriched samples may help predict patients' survival. These AdnaTest® CTC-enriched samples can be used in a high-throughput quantitative polymerase chain reaction (qPCR) analysis of gene expression, provided that the specificity of the assay for each individual gene is properly validated. The BioMark™ platform can be used for the simultaneous detection of ARFL and ARV7 and other genes in CTC-enriched samples from CRPC patients.
Authors: Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: N Engl J Med Date: 2014-09-03 Impact factor: 91.245
Authors: M Nakazawa; C Lu; Y Chen; C J Paller; M A Carducci; M A Eisenberger; J Luo; E S Antonarakis Journal: Ann Oncol Date: 2015-06-27 Impact factor: 32.976
Authors: Rhonda L Bitting; Patrick Healy; Susan Halabi; Daniel J George; Michael Goodin; Andrew J Armstrong Journal: Urol Oncol Date: 2015-01-13 Impact factor: 3.498
Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: Anieta M Sieuwerts; Jaco Kraan; Joan Bolt-de Vries; Petra van der Spoel; Bianca Mostert; John W M Martens; Jan-Willem Gratama; Stefan Sleijfer; John A Foekens Journal: Breast Cancer Res Treat Date: 2008-12-30 Impact factor: 4.872
Authors: Wendy Onstenk; Anieta M Sieuwerts; Jaco Kraan; Mai Van; Annemieke J M Nieuweboer; Ron H J Mathijssen; Paul Hamberg; Hielke J Meulenbeld; Bram De Laere; Luc Y Dirix; Robert J van Soest; Martijn P Lolkema; John W M Martens; Wytske M van Weerden; Guido W Jenster; John A Foekens; Ronald de Wit; Stefan Sleijfer Journal: Eur Urol Date: 2015-07-15 Impact factor: 20.096
Authors: Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman Journal: Genome Biol Date: 2002-06-18 Impact factor: 13.583
Authors: Andrea Lunardi; Ugo Ala; Mirjam T Epping; Leonardo Salmena; John G Clohessy; Kaitlyn A Webster; Guocan Wang; Roberta Mazzucchelli; Maristella Bianconi; Edward C Stack; Rosina Lis; Akash Patnaik; Lewis C Cantley; Glenn Bubley; Carlos Cordon-Cardo; William L Gerald; Rodolfo Montironi; Sabina Signoretti; Massimo Loda; Caterina Nardella; Pier Paolo Pandolfi Journal: Nat Genet Date: 2013-06-02 Impact factor: 38.330
Authors: James L Gulley; Peter Mulders; Peter Albers; Jacques Banchereau; Michel Bolla; Klaus Pantel; Thomas Powles Journal: Oncoimmunology Date: 2015-12-10 Impact factor: 8.110
Authors: Ingeborg E de Kruijff; Anieta M Sieuwerts; Wendy Onstenk; Jaco Kraan; Marcel Smid; Mai N Van; Michelle van der Vlugt-Daane; Esther Oomen-de Hoop; Ron H J Mathijssen; Martijn P Lolkema; Ronald de Wit; Paul Hamberg; Hielke J Meulenbeld; Aart Beeker; Geert-Jan Creemers; John W M Martens; Stefan Sleijfer Journal: Cancers (Basel) Date: 2019-08-20 Impact factor: 6.639
Authors: Emmanuel S Antonarakis; Andrew J Armstrong; Jun Luo; Changxue Lu; Landon C Brown Journal: Prostate Cancer Prostatic Dis Date: 2020-03-05 Impact factor: 5.554
Authors: Tanzila Khan; Therese M Becker; Kieran F Scott; Joseph Descallar; Paul de Souza; Wei Chua; Yafeng Ma Journal: Front Oncol Date: 2022-03-18 Impact factor: 6.244